Physician profile
Dev Sinha
NPI 1447542469
$9,187.69
in general payments reported to CMS, 2019-2025
45 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,621 · 2020: $1,270 · 2021: $524 · 2022: $1,074 · 2023: $1,176 · 2024: $1,471 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,699.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,272.40 | 2019-2024 | Eterna |
| Boston Scientific Corporation | $1,242.93 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Vertos Medical, INC. | $813.76 | 2019-2024 | Mild Device Kit |
| Medtronic, INC. | $756.56 | 2021-2024 | Intellis Adaptivestim |
| Royal Biologics, INC. | $690.37 | 2019-2025 | |
| Nevro Corp. | $669.08 | 2019-2023 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $372.80 | 2019-2025 | Relistor |
| Nuvasive, INC. | $339.88 | 2020-2023 | Acp |
| Saluda Medical Americas, INC. | $312.02 | 2023-2024 | Evoke, Evoke Scs |
| Flowonix Medical Incorporated | $207.37 | 2019 | |
| Collegium Pharmaceutical, INC. | $203.60 | 2019-2024 | Xtampza |
| Scilex Pharmaceuticals INC. | $203.25 | 2022-2025 | Ztlido |
| Stryker Corporation | $201.42 | 2022-2025 | |
| Abbvie INC. | $170.75 | 2022-2025 | |
| Painteq LLC | $144.23 | 2024 | Painteq |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $143.30 | 2019 | |
| Foundation Fusion Solutions, LLC | $132.93 | 2022-2025 | |
| Nalu Medical, INC. | $131.20 | 2022-2024 | Nalu Neurostimulation System |
| Depuy Synthes Sales INC. | $126.61 | 2019-2024 | Rigidloop, Monovisc |
| Biodelivery Sciences International, INC. | $108.63 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $101.65 | 2020-2023 | Xiaflex |
| Forte Bio-Pharma LLC | $74.89 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Virtus Pharmaceuticals LLC | $74.59 | 2020-2025 | Levorphanol Tartrate |
| Medtronic USA, INC. | $73.10 | 2019-2020 | |
| Biotronik Nro, INC. | $61.46 | 2024-2025 | Prospera |
| Kowa Pharmaceuticals America, INC. | $60.96 | 2023 | Seglentis |
| Allergan, INC. | $55.53 | 2019-2022 | |
| Si-Bone, INC. | $52.92 | 2020-2022 | |
| Horizon Therapeutics Plc | $43.44 | 2019-2020 | |
| Zyla Life Sciences, INC. | $42.94 | 2019-2020 | |
| Stratus Medical, LLC | $42.75 | 2020 | |
| Almatica Pharma LLC | $30.40 | 2022-2023 | Gralise |
| Tersera Therapeutics LLC | $26.08 | 2019-2021 | |
| Redhill Biopharma INC. | $25.31 | 2020 | |
| Axonics, INC. | $21.88 | 2022 | |
| Curonix LLC | $19.82 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $19.71 | 2024 | Sprint Pns System |
| Relievant Medsystems, INC. | $17.79 | 2019 | |
| Fidia Pharma USA INC. | $16.80 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.00 | 2019 | |
| Pacira Therapeutics, INC. | $14.77 | 2019 | |
| Pfizer INC. | $13.64 | 2019 | |
| Averitas Pharma INC. | $13.34 | 2023 | Qutenza |
| Shionogi INC | $13.12 | 2019 | |
| Ibsa Pharma INC. | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dev Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.